Cladribine in tablets in real clinical practice: Results of treatment of 267 patients with multiple sclerosis in Moscow
Authors:
- E. V. PopovaEPE. V. Popova
- V. B. SosinaVSV. B. Sosina
- S. N. SharanovaSSS. N. Sharanova
- S. N. ZolotovaSZS. N. Zolotova
- I. M. ShalabanovaISI. M. Shalabanova
- N. V. KhachanovaNKN. V. Khachanova
- M. V. DavydovskaiaMDM. V. Davydovskaia
- L. Yu. GorshkovaLGL. Yu. Gorshkova
- D. M. FekhretdinovaDFD. M. Fekhretdinova
- N. F. SmirnovaNSN. F. Smirnova
- E. V. PonevezhskayaEPE. V. Ponevezhskaya
- A. D. KukushkinaAKA. D. Kukushkina
Open Access
- 8 August 2025
- journal article
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 12,p. 120-127
Abstract
Introduction. Over the past 30 years, there has been a dramatic change in approaches to the treatment of multiple sclerosis (MS), due to the development of a large number of drugs with different mechanisms of action for the disease-modifying treatment (DMT) of MS.Aim. To form, based on the analysis of the obtained data, an optimal algorithm for the management of patients with MS receiving cladribine tablets in the conditions of real clinical practice.Materials and methods. A retrospective analysis of the data obtained on the background of therapy with cladribine in MS patients at the end of 2024 was conducted on the basis of the Moscow inter-district departments of MS. The data from outpatient records of MS patients treated with cladribine from 2021 to 2023 were used as research material. Data collection was carried out on the initial clinical and demographic characteristics of patients, as well as indicators of the effectiveness of therapy (average annual frequency of exacerbations, activity according to MRI data and progression according to the EDSS scale) and the presence of adverse reactions against the background of therapy with cladribine.Results. This publication presents the experience of using the drug cladribine in real clinical practice in 267 MS patients in Moscow in the period from 2021 to 2023. Patients who underwent two full annual courses of therapy showed a significant reduction in the mean annual frequency of exacerbations and brain MRI activity after the first year of therapy. There was also no significant increase in neurological deficits according to the EDSS scale. During the safety analysis, good tolerability of the drug was noted. The spectrum of adverse events and their frequency were comparable to the data of the instructions for medical use. Conclusion. Effective treatment of MS patients requires optimizing therapy, balancing benefits and risks, and long-term treatment planning from the moment of diagnosis. All these principles can be met with an understanding of the mechanism of action of the drugs and clear adherence to recommendations for monitoring the duration of washout periods when switching from one MS-modifying drug to another.Keywords
This publication has 22 references indexed in Scilit:
- Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group RecommendationsCanadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 2020
- Cladribine: mechanisms and mysteries in multiple sclerosisJournal of Neurology, Neurosurgery & Psychiatry, 2018
- The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple SclerosisClinical Pharmacokinetics, 2018
- Cladribine treatment of multiple sclerosis is associated with depletion of memory B cellsJournal of Neurology, 2018
- The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerationsJournal of Neurology, 2017
- Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple SclerosisEBioMedicine, 2017
- Impact of cladribine therapy on changes in circulating dendritic cell subsets, T cells and B cells in patients with multiple sclerosisJournal of the Neurological Sciences, 2013
- Risk of Natalizumab-Associated Progressive Multifocal LeukoencephalopathyNew England Journal of Medicine, 2012
- Cladribine inhibits cytokine secretion by T cells independently of deoxycytidine kinase activityJournal of Neuroimmunology, 2011
- CladribineClinical Neuropharmacology, 2011